Natural Compounds That Target Glioma Stem Cells
- PMID: 40559213
- PMCID: PMC12196138
- DOI: 10.3390/neurosci6020052
Natural Compounds That Target Glioma Stem Cells
Abstract
Gliomas are the most common central nervous system tumors and account for 30% of all primary brain tumors, 80% of all malignant ones, and the vast majority of deaths that are caused by brain tumors. Among them, glioblastoma multiforme has the most aggressive and invasive course. Due to its heterogeneity, it is difficult to treat, and one of the reasons for this are glioma stem cells (GSCs). Therapies such as radiotherapy and chemotherapy are used to treat gliomas but do not bring the expected results. Therefore, treatments targeting glioma stem cells are emerging. A promising strategy is to target GSCs with natural compounds. This review aims to describe the problem of glioma stem cells, the treatment of gliomas, and therapies based on natural compounds, which are promising for the future.
Keywords: glioblastoma; glioma stem cells; glioma treatment; natural compounds.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
Similar articles
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
-
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. doi: 10.3310/hta11450. Health Technol Assess. 2007. PMID: 17999840
-
Home treatment for mental health problems: a systematic review.Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150. Health Technol Assess. 2001. PMID: 11532236
-
68 Ga-PSMA-11 PET/CT Imaging in Brain Gliomas and Its Correlation With Clinicopathological Prognostic Parameters.Clin Nucl Med. 2023 Dec 1;48(12):e559-e563. doi: 10.1097/RLU.0000000000004903. Epub 2023 Oct 23. Clin Nucl Med. 2023. PMID: 37883060
-
Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis.Health Technol Assess. 2024 Aug;28(49):1-190. doi: 10.3310/TRRM4238. Health Technol Assess. 2024. PMID: 39252678 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources